Open AccessRelationship between angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and COVID-19 incidence or severe disease
Author(s) -
Gary Tse,
Jiandong Zhou,
Sharen Lee,
Wing Tak Wong,
Xintao Li,
Tong Liu,
Zhidong Cao,
Daniel Zeng,
Abraham Ka Chung Wai,
Ian Chi Kei Wong,
Bernard Man Yung Cheung,
Qingpeng Zhang
Publication year - 2021
Publication title -
journal of hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.249
H-Index - 172
eISSN - 1473-5598
pISSN - 0263-6352
DOI - 10.1097/hjh.0000000000002866
Subject(s) - medicine , angiotensin receptor blockers , covid-19 , odds ratio , incidence (geometry) , disease , angiotensin converting enzyme , severity of illness , univariate analysis , adverse effect , multivariate analysis , infectious disease (medical specialty) , physics , blood pressure , optics
Angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) may be associated with higher susceptibility of COVID-19 infection and adverse outcomes. We compared ACEI/ARB use and COVID-19 positivity in a case-control design, and severity in COVID-19 positive patients.